From WHO to GLP‑1: The week’s biggest health debates & India’s malaria challenge
The World Health Organization (WHO) issued its first global guideline on the use of GLP-1 receptor agonist medicines for the long-term treatment of obesity in adults in December 2025, covering three agents: liraglutide, semaglutide, and tirzepatide.
The WHO guideline triggered a global debate about equitable access to these high-cost anti-obesity drugs, particularly for low- and middle-income countries.
Simultaneously, India faces a dual challenge in public health: while making significant progress toward its 2030 malaria elimination target, a new threat has emerged from the invasive urban mosquito Anopheles stephensi, which threatens to reverse gains in malaria control.
A recent health analysis placed both debates — over GLP-1 drug equity and India's malaria challenge — as among the most consequential health policy discussions of the week.
GLP-1 Receptor Agonists — Mechanism and Global Significance
GLP-1 (Glucagon-Like Peptide-1) receptor agonists are a class of medicines that mimic the action of the naturally occurring GLP-1 hormone, which is released from the gut after eating. They stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite — together producing significant and sustained weight loss. Originally developed for Type 2 diabetes management, GLP-1 receptor agonists have transformed the treatment of obesity. The three agents covered by the WHO guideline are: liraglutide (Victoza/Saxenda), semaglutide (Ozempic/Wegovy), and tirzepatide (Mounjaro/Zepbound — a dual GLP-1/GIP agonist). Clinical trials show tirzepatide can produce up to 22.5% body weight reduction; semaglutide up to 15–21%; liraglutide is less potent but established.
Key Details
- GLP-1: Incretin hormone secreted by intestinal L-cells post-meal; stimulates insulin, suppresses glucagon, reduces appetite.
- WHO December 2025 guideline: First global guidance on GLP-1 medicines for obesity — covers liraglutide, semaglutide, tirzepatide.
- Tirzepatide: Dual GLP-1/GIP agonist; most potent for weight loss (~22.5% body weight reduction in trials).
- Semaglutide: GLP-1 agonist; used in both injectable (Wegovy/Ozempic) and oral (Rybelsus) forms.
- Global anti-obesity drugs market: Estimated at $19.6 billion (2025), projected to reach ~$104.9 billion by 2035.
- Key debate: Affordability and equitable access for low- and middle-income countries, including India.
The WHO guideline gives clinical legitimacy to GLP-1 drugs for obesity — but the global debate is whether this legitimacy translates into accessible treatment, especially for developing nations where obesity burdens are rising but drug costs remain prohibitive.
WHO's Role in Global Health Governance
The World Health Organization (WHO) is the specialized agency of the United Nations responsible for international public health. It was established in 1948 and is headquartered in Geneva, Switzerland. India is a founding member. WHO's functions include setting international health norms and standards, providing technical guidance to member states, coordinating international health emergencies (under the International Health Regulations, 2005), and managing the prequalification of medicines. WHO guidelines — while not legally binding — carry significant normative weight: they inform national formularies, insurance coverage decisions, and procurement policies globally. The WHO's Model List of Essential Medicines (updated biennially) influences what medicines are prioritized for national health systems.
Key Details
- Established: 7 April 1948 (World Health Day is commemorated on this date annually).
- Headquarters: Geneva, Switzerland.
- India: Founding member; part of WHO's South-East Asia Regional Office (SEARO), headquartered in New Delhi.
- International Health Regulations (IHR), 2005: Binding international instrument for reporting and managing health emergencies.
- WHO Essential Medicines List: Updated every two years; influences national drug policy.
- GLP-1 guideline (December 2025): First WHO global guidance on this drug class for obesity — not yet on Essential Medicines List.
The WHO GLP-1 guideline sets a new normative benchmark; whether and how India adopts it into national treatment guidelines and insurance coverage is the downstream policy question.
India's Malaria Elimination Programme
India has made substantial progress in reducing its malaria burden over the past decade. The country follows a phased National Strategic Plan for Malaria Elimination (2023–2027), targeting zero indigenous cases by 2027 and complete elimination by 2030 — aligned with the WHO's Global Technical Strategy for Malaria 2016–2030. Malaria in India is primarily caused by two Plasmodium species: P. falciparum (the more deadly form, prevalent in tribal and forested areas) and P. vivax (more widespread, with relapse potential). Annual Parasite Incidence (API), the key surveillance metric, has declined from 3.29 per thousand population in 1995 to 0.18 per thousand in 2024. Positive cases fell from approximately 1.09 million in 2016 to 2,55,500 in 2024 — a 76% reduction. Deaths fell by 74% in the same period.
Key Details
- National Framework for Malaria Elimination: 2016–2030; phased targets.
- National Strategic Plan (2023–2027): Zero indigenous cases by 2027.
- Annual Parasite Incidence (API): Dropped from 3.29 (1995) to 0.18 (2024) per 1,000 population.
- Cases (2024): ~2,55,500 (down 76% from 2016).
- Deaths (2024): 86 (down 74% from 331 in 2016).
- Primary vectors: Anopheles culicifacies (rural), Anopheles stephensi (urban, invasive).
- Nodal agency: National Centre for Vector Borne Diseases Control (NCVBDC), under Ministry of Health and Family Welfare.
- Surveillance platform: Integrated Health Information Platform (IHIP).
India's malaria trajectory is among the world's most dramatic — but the gains are now threatened by the emergence of an urban vector, making this a live policy challenge at exactly the point when elimination seemed achievable.
Anopheles stephensi — The Urban Malaria Threat
Anopheles stephensi is an invasive mosquito species that poses a distinct and growing threat to India's malaria elimination goals. Unlike traditional rural malaria vectors such as Anopheles culicifacies, A. stephensi thrives in urban environments, breeding in artificial water containers — overhead tanks, construction site water, tyres, and flowerpots — that are common features of rapidly growing Indian cities. It efficiently transmits both P. falciparum and P. vivax. Originally an Asian urban species, A. stephensi has expanded its range into Africa (first reported in Djibouti in 2012), raising alarm for WHO. In India, it has been detected in several metropolitan areas. Its presence in cities — where surveillance and conventional vector control are harder to implement — threatens to create new endemic urban foci just as rural malaria cases are declining.
Key Details
- Species: Anopheles stephensi — invasive urban malaria vector.
- Breeding habitat: Artificial containers (tanks, tyres, construction sites) in urban environments.
- Transmits: Both P. falciparum and P. vivax.
- Geographic spread: Originally Asian; detected in Africa (Djibouti, 2012) — now classified as WHO priority invasive vector.
- India concern: Detected in multiple Indian cities; urban construction boom accelerating breeding sites.
- Control challenge: Conventional rural vector control strategies are poorly adapted to urban environments.
- India's Malaria Elimination Technical Report 2025: Flagged A. stephensi as a national-level threat to the 2030 target.
The A. stephensi threat represents a structural challenge to India's elimination strategy — requiring city-specific surveillance and vector control frameworks that are different from the rural playbook that drove the 76% case reduction.
- WHO issued its first GLP-1 obesity treatment guideline in December 2025 (covers liraglutide, semaglutide, tirzepatide).
- Tirzepatide produces up to 22.5% body weight reduction; semaglutide up to 21%; liraglutide is less potent.
- Global anti-obesity drug market: $19.6 billion (2025), projected ~$104.9 billion by 2035.
- India's malaria cases: ~2,55,500 in 2024, down 76% from ~1.09 million in 2016.
- India's malaria deaths: 86 in 2024, down 74% from 331 in 2016.
- Annual Parasite Incidence (API): 0.18 per 1,000 (2024), down from 3.29 in 1995.
- India's target: Zero indigenous malaria cases by 2027; complete elimination by 2030.
- Anopheles stephensi: Urban invasive vector; breeds in artificial containers; transmits P. falciparum and P. vivax.
- A. stephensi was first detected in Africa (Djibouti) in 2012; now flagged as a WHO-priority invasive mosquito.
- WHO established: 7 April 1948; India is a founding member; SEARO HQ is in New Delhi.
- Nodal agency for malaria in India: NCVBDC, under Ministry of Health and Family Welfare.